Izumo

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Childhood cancers3 trials
• Chronic spontaneous urticaria3 trials
• Acute lymphoblastic leukaemia1 trial
• Chronic myeloid leukaemia1 trial
• Dermatomyositis and polymyositis (myositis)1 trial
• Diffuse large B-cell lymphoma1 trial
• Lung cancer1 trial
• Lupus (SLE)1 trial
• Multiple sclerosis1 trial

Phase

• Phase 34 trials
• Phase 22 trials

Status

• Active, not recruiting4 trials
• Completed4 trials
• Recruiting1 trial

Lead sponsor

• Novartis Pharmaceuticals9 trials

Running trials

• Active, not recruiting

  Phase 2 Study of Rapcabtagene Autoleucel in Myositis

  NCT06665256· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

  NCT06581198· Phase 2· Novartis Pharmaceuticals· Source

• Active, not recruiting

  24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up

  NCT05677451· Phase 3· Novartis Pharmaceuticals· Source

• Active, not recruiting

  An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

  NCT05513001· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Study of Out of Specification for Tisagenlecleucel

  NCT04094311· Phase 3· Novartis Pharmaceuticals· Source

  Contact: Novartis Pharmaceuticals

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute lymphoblastic leukaemia1 recruiting
• Childhood cancers1 recruiting
• Diffuse large B-cell lymphoma1 recruiting

Closed trials

• Completed

  Special Drug Use-results Surveillance of Scemblix Tablets

  NCT05421091· Novartis Pharmaceuticals· Source

• Completed

  A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines

  NCT05048342· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen

  NCT04940065· Novartis Pharmaceuticals· Source

• Completed

  Special Drug Use-results Surveillance of Tabrecta Tablets

  NCT04575025· Novartis Pharmaceuticals· Source